Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER negative, HER2-negative, PR negative status confers therapeutic sensitivity to Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with chemotherapy for reimbursement as a treatment option for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence. This cited regimen is specifically for pembrolizumab 400mg in combination with weekly carboplatin AUC 1.5 and paclitaxel 80mg/m^2 followed by dose dense doxorubicin and cyclophosphamide (AC 60/600) therapy.
This statement is based on a regulatory approval from the Health Service Executive:
Pembrolizumab in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.